Wall Street brokerages expect that Axsome Therapeutics Inc (NASDAQ:AXSM) will post ($0.51) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Axsome Therapeutics’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.43). Axsome Therapeutics reported earnings of ($0.32) per share in the same quarter last year, which would suggest a negative year over year growth rate of 59.4%. The firm is expected to report its next earnings report on Thursday, March 12th.
On average, analysts expect that Axsome Therapeutics will report full-year earnings of ($1.77) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.69). For the next financial year, analysts forecast that the business will post earnings of ($1.60) per share, with EPS estimates ranging from ($2.01) to ($0.98). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.15).
Several equities research analysts have commented on the company. BTIG Research boosted their price objective on Axsome Therapeutics to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 30th. Zacks Investment Research upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 19th. Guggenheim boosted their price objective on Axsome Therapeutics from $65.00 to $48.00 in a research note on Wednesday, December 4th. HC Wainwright restated a “buy” rating and set a $200.00 target price (up from $170.00) on shares of Axsome Therapeutics in a report on Tuesday, December 24th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $125.00 target price (up from $104.00) on shares of Axsome Therapeutics in a report on Monday, December 30th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $99.80.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its holdings in shares of Axsome Therapeutics by 263.1% during the 2nd quarter. BlackRock Inc. now owns 1,690,522 shares of the company’s stock worth $43,531,000 after purchasing an additional 1,224,935 shares during the last quarter. VHCP Management III LLC boosted its holdings in shares of Axsome Therapeutics by 50.9% during the 2nd quarter. VHCP Management III LLC now owns 1,611,329 shares of the company’s stock worth $41,492,000 after purchasing an additional 543,285 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Axsome Therapeutics by 27.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,152,285 shares of the company’s stock worth $29,671,000 after purchasing an additional 250,498 shares during the last quarter. VHCP Management II LLC lifted its holdings in Axsome Therapeutics by 56.1% in the second quarter. VHCP Management II LLC now owns 892,946 shares of the company’s stock valued at $22,993,000 after acquiring an additional 320,990 shares during the last quarter. Finally, State Street Corp lifted its holdings in Axsome Therapeutics by 12.0% in the third quarter. State Street Corp now owns 729,682 shares of the company’s stock valued at $14,769,000 after acquiring an additional 78,209 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.
NASDAQ:AXSM opened at $90.69 on Monday. Axsome Therapeutics has a 12 month low of $7.63 and a 12 month high of $109.94. The stock has a 50 day moving average of $75.93 and a two-hundred day moving average of $37.76. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 2.80. The firm has a market cap of $3.12 billion, a P/E ratio of -78.86 and a beta of 3.39.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.